AstraZeneca Imjudo, Imfinzi combo approved for non–small cell lung cancer
da-kuk         

The US FDA has approved a combination of AstraZeneca's (NASDAQ:AZN) Imjudo (tremelimumab) + Imfinzi (durvalumab) and platinum-based chemotherapy for metastatic nonâsmall cell lung cancer.
The approval is for those who possess an EGFR mutation or ALK alteration.
Approval was based on results on the phase 3 POSEIDON trial which showed that when Imjudo was added to Imfinzi + chemo, it led to a 25% increase in overall survival compared to chemo alone.